XML 110 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Segments and Geographic Information
 12 Months Ended
Sep. 27, 2014
Segment Reporting [Abstract]  
Business Segments and Geographic Information
Business Segments and Geographic Information
The Company reports segment information in accordance with ASC 280, Segment Reporting. Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions about how to allocate resources and assess performance. The Company’s chief operating decision maker is the chief executive officer, and the Company’s reportable segments have been identified based on the types of products manufactured and the end markets to which the products are sold. Each reportable segment generates revenue from either the sale of medical equipment and related services and/or sale of disposable supplies, primarily used for diagnostic testing and surgical procedures. The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income (loss) adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset impairment charges, contingent consideration charges, restructuring and divestiture charges, and other one-time or unusual items, and related tax effects.
Identifiable assets for the four principal reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its four reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no intersegment revenues. Segment information for fiscal 2014, 2013, and 2012 was as follows:
 
 
Years ended
 
 
September 27,
2014
 
September 28,
2013
 
September 29,
2012
Total revenues:
 
 
 
 
 
 
Diagnostics
 
$
1,186.8

 
$
1,189.8

 
$
718.1

Breast Health
 
944.7

 
905.1

 
875.8

GYN Surgical
 
307.9

 
307.1

 
313.1

Skeletal Health
 
91.3

 
90.3

 
95.6

 

$
2,530.7


$
2,492.3

 
$
2,002.6

Operating income (loss):
 
 
 
 
 
 
Diagnostics
 
$
48.7

 
$
(1,149.1
)
 
$
(32.8
)
Breast Health
 
187.6

 
216.1

 
186.1

GYN Surgical
 
30.3

 
19.7

 
(51.9
)
Skeletal Health
 
13.1

 
7.1

 
12.3

 
 
$
279.7

 
$
(906.2
)
 
$
113.7

Depreciation and amortization:
 
 
 
 
 
 
Diagnostics
 
$
376.0

 
$
369.8

 
$
197.3

Breast Health
 
41.7

 
40.1

 
42.9

GYN Surgical
 
104.6

 
105.2

 
103.8

Skeletal Health
 
0.9

 
0.9

 
1.8

 

$
523.2


$
516.0

 
$
345.8

Capital expenditures:
 
 
 
 
 
 
Diagnostics
 
$
52.2

 
$
51.6

 
$
44.9

Breast Health
 
10.0

 
16.4

 
9.8

GYN Surgical
 
8.0

 
9.1

 
12.2

Skeletal Health
 
0.4

 
0.6

 
0.2

Corporate
 
9.6

 
12.4

 
11.6

 

$
80.2


$
90.1

 
$
78.7

 
 
 
September 27,
2014
 
September 28,
2013
 
September 29,
2012
Identifiable assets:
 
 
 
 
 
 
Diagnostics
 
$
4,383.5

 
$
4,667.9

 
$
6,170.5

Breast Health
 
859.8

 
932.2

 
956.1

GYN Surgical
 
1,748.2

 
1,849.5

 
1,944.4

Skeletal Health
 
26.1

 
33.5

 
32.8

Corporate
 
1,397.1

 
1,517.7

 
1,373.3

 
 
$
8,414.7

 
$
9,000.8

 
$
10,477.1


In fiscal 2013, the Company recorded a goodwill impairment charge of $1.1 billion related to its Molecular Diagnostics reporting unit, which is in its Diagnostics segment. In fiscal 2012, the Company recorded a goodwill impairment charge of $5.8 million related to its MammoSite reporting unit, which is in its Breast Health segment.
The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “All others” designation includes Canada, Latin America and the Middle East.
Revenues by geography as a percentage of total revenues were as follows:
 
 
 
Years ended
 
 
September 27,
2014
 
September 28,
2013
 
September 29,
2012
United States
 
75
%
 
75
%
 
74
%
Europe
 
13
%
 
13
%
 
12
%
Asia-Pacific
 
8
%
 
8
%
 
8
%
All others
 
4
%
 
4
%
 
6
%
 
 
100
%
 
100
%
 
100
%


The Company’s property, plant and equipment, net are geographically located as follows:
 
 
September 27, 2014
 
September 28, 2013
 
September 29, 2012
United States
 
$
366.8

 
$
386.0

 
$
405.1

Costa Rica
 
27.9

 
29.3

 
30.5

Europe
 
56.0

 
61.5

 
59.9

All other countries
 
11.2

 
14.7

 
12.5

 
 
$
461.9

 
$
491.5

 
$
508.0